Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Heart Failure

In brief

The purpose of this study was to assess the safety of repeat doses of serelaxin in chronic heart failure.

Key facts

Study ID
NCT01982292
Run by
Novartis Pharmaceuticals
People needed
321
Starts
2014-05-01
Expected to finish
2015-09-01
Last updated by the study team
2016-11-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.